Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

ALEC - Alector, Inc. Последние новости | Finranks

Home

/

ALEC

A

Alector, Inc. (ALEC)

NMS – Цена в реальном времени. Валюта: USD

2.08

-0.01 (-0.72%)

Рынок открыт: Aug 12, 2026, 1:49 PM EDT

2.09

0.00 (0.00%)

Предыдущая сессия: Aug 11, 2026, 7:40 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.3 per share a year ago.

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's disease (AD). Continued progress across AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)).

Видео

No Data

There is no data to display

Пресс-релизы

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's disease (AD). Continued progress across AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)).